Power Move: Cutera, L’Oréal Partner to Bring SkinCeuticals Products to Japan

Cutera and its Japanese subsidiary, Cutera KK, are joining forces with L’Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan.

“We are excited about this collaboration with L’Oréal Japan Co. to bring SkinCeuticals’ renowned skincare innovations to aesthetic providers in Japan,” says Brent Hauser, Cutera’s International President, in a news release. “This agreement underscores our commitment to supporting our existing customer base by expanding access to high-quality skincare solutions that meet the unique needs of medical clinics and their patients.”

Under the terms of the agreement, the partnership will initially span three years, with options for renewal. As part of the collaboration, L’Oréal Japan Co. will provide comprehensive marketing and advertising support to enhance the visibility and reach of SkinCeuticals products within the medical community.

Cutera plans to introduce the SkinCeuticals product line to customers in Japan during the fourth quarter of this year. The company expects the financial impact of the distribution agreement to be immaterial in 2024.

Mindera Health Secures $14 Million to Advance Psoriasis Precision Medicine Test

Mindera Health Inc. closed on a $14M convertible note financing, led by Mountain Group Partners and other existing investors in anticipation of a Series B financing in 2025, to support the continued commercialization of Mindera’s lead product, Mind.Px.

Mind.Px is the first psoriasis precision medicine test. It aims to eliminate today’s trial-and-error approach to psoriasis treatment by providing physicians, patients, and payors with a tool to guide the individual patient to an efficacious drug class based on their biomarker profile.

InMode Introduces IgniteRF Platform

InMode Ltd. is rolling out IgniteRF, a minimally invasive workstation that includes nine technologies which offer soft tissue contraction across multiple tissue depths.

The IgniteRF platform features BodyTite, FaceTite, Morpheus8, and now the QuantumRF family of products. QuantumRF is a new, minimally invasive technology which deploys fractionated radiofrequency to maximal depths.  It includes two lightweight and versatile cannulas, QuantumRF 10 for small, more delicate treatment zones and QuantumRF 25 for larger treatment zones.

“IgniteRF marks a significant milestone for InMode, with continued innovation to make our best in-class technology faster, smarter, and even more exceptional results,” says Dr. Michael Kreindel, CTO and Co-founder of InMode.

Galderma’s Liquid Toxin Receives Positive Decision for Use in Europe

Galderma’s Relfydess (RelabotulinumtoxinA) received a positive decision for use in Europe, and national approvals within the sixteen concerned countries are now under finalization, the Compnay reports.

Galderma completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess  (RelabotulinumtoxinA – previously referred to as QM1114).

Following the completion of the DCP, national approvals in the 16 concerned countries are now under finalization. Relfydess also received a marketing authorization in Australia earlier this year. Regulatory applications for Relfydess  for the treatment of frown lines and crow’s feet will continue to be submitted and assessed by additional authorities globally.

Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months for frown lines and crow’s feet. It is optimized for simple volumetric dosing, without reconstitution, to increase ease of use and help ensure consistent dose/volume.

This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) clinical trial program, which enrolled more than 1,900 participants. Results showed:

• Improvement in both frown lines and crow’s feet versus placebo:

o          In READY-1 and READY-2, treatment with Relfydess demonstrated a 96.3% none-or-mild responder rate for frown lines and 87.2% for crow’s feet, after one month, vs 4.5% and 11.9% for placebo, respectively.

• Onset of action as soon as day one:

o          In READY-1 and READY-2, 39% of patients reported improvements for frown lines and 34% reported improvements for crow’s feet from day one.

• Sustained results for six months:

o          In READY-1 and READY-2, up to 75% of patients maintained improvements for six months.

o          At month one, up to 96% achieved none-or-mild frown lines and crow’s feet, which was sustained for six months in almost a quarter of patients.

• Patient satisfaction was maintained for six months following treatment.